

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 March 2025 (27.03.2025)



(10) International Publication Number
WO 2025/061107 A1

(51) International Patent Classification:

A61P 31/16 (2006.01) A61K 39/00 (2006.01)
A61K 39/12 (2006.01)

(21) International Application Number:

PCT/CN2024/119839

(22) International Filing Date:

19 September 2024 (19.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202311244673.7 22 September 2023 (22.09.2023) CN
202411236824.9 04 September 2024 (04.09.2024) CN

(71) Applicants: **ARGORNA PHARMACEUTICALS CO., LTD.** [CN/CN]; 2nd And 4th Floor, Building A, 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN). **GUANGZHOU RIBOBIO CO., LTD.** [CN/CN]; No. 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN).

(72) Inventors: **ZHANG, Bill Biliang**; No. 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN). **CHENG, Nan**; No. 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN). **MA, Lin**; No. 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN). **LI, Man**; No. 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN). **ZHONG,**

Huiling; No. 7 Suida Street, Huangpu District, Guangzhou, Guangdong 510530 (CN).

(74) Agent: **KANGXIN PARTNERS, P.C.**; Floor 16, Tower A, Indo Building, A48 Zhichun Road, Haidian District, Beijing 100098 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITION COMPRISING MRNA ENCODING INFLUENZA VIRUS HA PROTEIN AND USE THEREOF




Fig. 5

(57) Abstract: Provided are an immunogenic composition comprising one or more influenza virus surface hemagglutinin proteins (HA proteins) or an mRNA encoding same, and use thereof for preventing or treating a disease or condition related to influenza virus infection.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))